Home・Stock List・Xencor Inc

Xencor Inc

Closed

SectorHealthcare

19.36 -0.62

Buy Sell

Overview

Share price change

24h

Current

Min

18.87

Max

19.85

Key metrics
By Trading Economics
Income	-214M -129M
Sales	-24M 4.5M
EPS	-1.71
Profit margin	-2,854.65
Employees	260
EBITDA	-127M -121M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+23.4% upside

Dividends
By Acuity
Next Earnings	4 Aug 2026

Market Stats
By TradingEconomics
Market Cap	404M 1.4B
Previous open	19.98
Previous close	19.36

News Sentiment

By Acuity

50%

163 / 340 Healthcare

Xencor Inc Chart

Past performance is not a reliable indicator of future results.

Related News

24 Jul 2026, 19:11 UTC

Xencor Inc shares are lower in Friday's session, reflecting broader market trends. No specific news was identified to explain the price movement.

22 Jul 2026, 20:06 UTC

Xencor Inc shares are lower today, retracing from an earlier peak. Broader market sentiment is affected by uncertainty ahead of the Federal Reserve meeting.

21 Jul 2026, 19:02 UTC

Social Media

Xencor Inc. shares reached a new 52-week high, driven by developments in RCC related to ENPP3 and immuno-oncology efforts involving TL1A.

20 Jul 2026, 19:41 UTC

Social Media

Xencor Inc's shares are higher as clinical results are accepted for presentation at the ESMO conference, with a Phase 3 trial planned for 2027.

Peer Comparison

Price change

Xencor Inc Forecast

Price Target

By TipRanks

23.4% upside

12 Months Forecast

Average 24.1 USD 23.4%

High 38 USD

Low 13 USD

Based on 11 Wall Street analysts offering 12 month price targets forXencor Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Xencor Inc - Dist in the past 3 months.

Sentiment

By Acuity

163 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.